? SHARED RESOURCES MANAGEMENT The Ohio State University Comprehensive Cancer Center (OSUCCC) manages and supports 16 CCSG-funded Shared Resources (SRs) and is proposing two developing shared resources in this application. The goals of the OSUCCC SRs are to support OSUCCC members by providing specialized technologies, services, and expertise that maximize quality and speed of service, while maintaining cost-effectiveness and quality control. The SRs support all five Research Programs and are managed by faculty from seven different colleges and Nationwide Children?s Hospital. Most of the SRs are centrally located and in close proximity to OSUCCC members.
The Specific Aims for Shared Resource Management are to: 1) evaluate for need, and establish new specialized technologies, services and expertise that enhance scientific interaction and productivity; 2) ensure that the SRs provide cost-effective, reliable, and quality-controlled technologies, services and expertise; 3) support SRs through budget planning, laboratory management systems, and sustainability; and 4) establish policies for SR access and use. The OSUCCC directly manages 13 of the 16 SRs, and the others are jointly managed as institutional SRs that follow NCI policies. Reporting to the OSUCCC Director, the SRs are led by Sharyn Baker, PharmD, PhD, Associate Director for Shared Resources. Dr. Baker works with Heather Hampel MS, LGC, Associate Director for Biospecimen Research for integration of biospecimen services with the SRs. Dr. Baker leads the Shared Resource Team Leader (SRTL) committee that oversees SR management and implementation of the scientific vision. The SRTL monitors quality and user satisfaction through user surveys and user committees. SR development and evaluation is provided to Dr. Baker from the Associate Directors Committee, Program Leaders, and the External Scientific Advisory Board. Shared Resource Management operations include ensuring compliance with OSUCCC policies (prioritization of use and access, budgets, billing, and quality control) and compliance with OSU Office of Research policies and the federal Uniform Guidance. For the evaluation of new instrumentation and services, Dr. Baker manages the Intramural Research Program (IRP) that provides external peer review of SR applications, evaluating scientific merit and planned usage ($3.4M awarded this grant cycle. Overall support to the SRs over the last grant cycle has been $18M, allowing for all of the SRs to have been enhanced and offer new services. Future plans for each SR are accounting for planned increased usage due to the OSUCCC strategic research priorities and planned recruitment. The OSUCCC provides over $9M in overall support of the SRs annually, The OSUCCC is requesting a total of $1,971,340 in CCSG funding, 8.9% of the total support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090000
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications